CLINICAL_TRIALS
trial_result
· 2017-02-03
Clinical Trial Update: Glucarpidase Effect on Severe Delayed HDM-clearance in Children Treated With High-dose Mtx in ALL [Phase 3]
Summary
Phase 3 trial assessing glucarpidase impact on severe delayed HDM clearance in children with high-dose methotrexate-treated acute lymphoblastic leukemia.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Nordic Society for Pediatric Hematology and Oncology | Conditions: Acute Lymphoblastic Leukemia (ALL) | Phase 3 | Status: COMPLETED | Results posted: 2017-02-03